<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>14</Volume>
				<Issue>6</Issue>
				<PubDate PubStatus="epublish">
					<Year>2013</Year>
					<Month>06</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Prognostic Value of Phosphorylated mTOR/RPS6KB1 in Nonsmall Cell Lung Cancer</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>3725</FirstPage>
			<LastPage>3728</LastPage>
			<ELocationID EIdType="pii">27848</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>&lt;b&gt;Background:&lt;/b&gt; The mammalian target of rapamycin (mTOR) /RPS6KB1 activation has recently been implicatedin tumour development, but its role in lung cancer remains unclear. The aim of this study was to explore the roleof mTOR/RPS6KB1 signaling pathway in non-small-cell lung cancer (NSCLC). &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: Immunohistochemistrywas performed to assess the expression of phosphorylated mammalian target of rapamycin (p-mTOR) and itsdownstream ribosomal phosphorylated RPS6KB1 (p-RPS6KB1) in NSCLC patients. We also analyzed p-mTOR/p-RPS6KB1 protein expression in 45 fresh NSCLC tissues using Western blotting. &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: The expressionlevel of p-mTOR and p-RPS6KB1 was significantly higher in NSCLC tumor specimens than that in adjacentnoncancerous normal lung tissues (P&lt;0.01). p-mTOR expression correlated with p-RPS6KB1. Furthermore,high expression level of p-mTOR or p-RPS6KB1 in NSCLC was associated with a shorter overall survival (bothP&lt;0.01). Multivariate analysis indicated high level of p-mTOR expression was an independent prognostic factor(HR=2.642, 95%CI 1.157–4.904, p=0.002). &lt;br/&gt;&lt;b&gt;Conclusions&lt;/b&gt;: p-mTOR and p-RPS6KB1 could be useful prognosticmarkers for NSCLC.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">non-small-cell lung cancer</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Biomarker</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">mTOR/RPS6KB1</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Prognosis</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_27848_2ff912c9135f50324e859b36a0cc7055.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
